Sotrovimab

Names

[ Name ]:
Sotrovimab

Biological Activity

[Description]:

Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> SARS-CoV

[In Vitro]

Sotrovimab 可以中和 SARS-CoV-2 和 SARS-CoV，但不能直接阻断病毒受体结合[2]。 Sotrovimab (100 μg/mL, 注射入培养基, 持续 200 s, v=30 μL/min) 能有效结合表面表达的 SARS-CoV-2 S[3]。 Sotrovimab (0.3 ng/mL-20 mg/mL; 30 min) 对 SARS-CoV-2 伪型病毒具有体外中和作用，对Alpha、Beta、Gamma、Delta 和 Kappa 变种病毒的 IC50 分别为 187.2 ng/mL、71.9 ng/mL、73.11 ng/mL、51.3 ng/mL 和 118.64 ng/mL[3]。

[In Vivo]

Sotrovimab (5 mg/kg, 10 mL; 经静脉导管给药; 单次剂量) 可对雌性食蟹猴肺部的易感变异进行长达 28 天的保护性暴露[3]。

[References]

[1]. Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950.

[2]. Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824.

[3]. Cathcart A L, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2[J]. biorxiv, 2022: 2021.03. 09.434607.

[4]. Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.